Posts Tagged ‘prevention’

November 24th, 2014

Selections from Richard Lehman’s Literature Review: November 24th

This week’s topics include the PROTECT-AF trial, the association of inpatient vs. outpatient onset of STEMI with treatment and clinical outcomes, and more.

June 9th, 2014

Selections from Richard Lehman’s Literature Review: June 9th

This week’s topics include the CORONARY trial, the association of azithromycin with mortality and CV events among older patients hospitalized with pneumonia, and more.

May 8th, 2014

Selections from Richard Lehman’s Literature Review: May 8th

This week’s topics include darapladib for preventing ischemic events in stable CHD, the DAMASCENE analysis, a review of John Brush’s new book, and more.

January 22nd, 2014

SERIES: Making Sense of the New Prevention Guidelines — The View from Clinical Practice

A series of clinical vignettes involving decisions affected by the recently published prevention guidelines (JNC 8, ACC/AHA, ESC)

December 23rd, 2013

Statins: Targeting Risk, but Risking Diabetes?


Emma Morton-Eggleston and Richard Lehman share their correspondence with us, in which they debate whether it’s worth using statins to target CV risk if they might increase other risks, such as diabetes.

November 20th, 2013

AHA.13: Good until the End

On the last afternoon at AHA.13, a poster on an experimental preventive treatment catches the eye of a cardiology Fellow .

September 3rd, 2013

A Transatlantic Taste

A fellow wonders about worldwide differences in clinical and research approaches in cardiology, as she attends a session on a controversial area that sits uncomfortably alongside the weight-loss message central to American efforts to improve cardiovascular health.

April 5th, 2013

Cardio-Oncology: Who Needs It?

Our panel sketches out the scope of this growing discipline.

November 12th, 2012

Selections from Richard Lehman’s Literature Review: November 12th

This week’s topics include multivitamins for the prevention of CVD in men, the TRILOGY ACS trial, statin use and reduced cancer mortality, and more.

November 16th, 2011

Evacetrapib – The New Wonder Drug?

Impressive safety and efficacy data on evacetrapib—but it’s too early give odds on whether it’s a true wonder drug or a nightmare like its fellow CETP inhibitor, torceptrapib